Bank of America
ADIL

Bank of America’s Adial Pharmaceuticals ADIL Stock Holding History

Bank of America’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$45 – 5703
2025
Q4 		$45 Buy
8
+1
+14% +$8 ﹤0.01% 6975
2025
Q3 		$64 Buy
7
+4
+133% +$39 ﹤0.01% 7954
2025
Q2 		$22 Buy
3
+1
+50% +$15 ﹤0.01% 8230
2025
Q1 		$35 Hold
2
– – ﹤0.01% 8036
2024
Q4 		$53 Hold
2
– – ﹤0.01% 7850
2024
Q3 		$52 Sell
2
-26
-93% -$678 ﹤0.01% 7834
2024
Q2 		$792 Buy
+28
New +$1.06K ﹤0.01% 7269
2020
Q3 		– Sell
-240
Closed -$209K – 6854
2020
Q2 		$209K Buy
+240
New +$217K ﹤0.01% 5216
2019
Q4 		– Sell
-1
Closed -$1K – 7038
2019
Q3 		$1K Buy
+1
New +$1.06K ﹤0.01% 7069
2018
Q4 		– Sell
-1
Closed -$1K – 7062
2018
Q3 		$1K Buy
+1
New +$2.08K ﹤0.01% 7094

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RWML
RAFFA WEALTH MANAGEMENT, LLC Washington, District of Columbia $793M AUM 13.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Bank of America's ADIL Position: Q1 2026 in Review

Bank of America sold out of Adial Pharmaceuticals (ADIL) in Q1 2026, closing a stake of 8 shares — an estimated $45 sold.

Bank of America first reported a position in ADIL in Q3 2018 and held it in 10 quarters. The position peaked at $209K in Q2 2020. 15 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Bank of America reported no remaining Adial Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 8 Adial Pharmaceuticals shares in Q1 2026, an estimated $45.
  • Bank of America first reported a position in Adial Pharmaceuticals in Q3 2018 and held it in 10 quarters.
  • Bank of America's Adial Pharmaceuticals position peaked at $209K in Q2 2020.
  • 15 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.